Taken together, we discovered that RNF220 functioned as an oncogenic factor by promoting the stemness the progression of colon cancer via the USP22-BMI1 axis, shedding lights on RNF220 as a potential therapeutic targets for colon cancer treatment from bench to clinic. Here, BMI1 is linked to malignant colon neoplasm.